Related Experiment Video
Updated: Apr 8, 2026
An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
Published on: November 3, 2010
The NRF2 readout beyond genotyping†
Yukako Suzuki1,2,3, Maolin Ge1
1Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA.
Abstract:
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, and many patients derive limited benefit from current systemic therapies. Until now, clinical and translational efforts have largely focused on recurrent genomic alterations in the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (NRF2) axis, yet mutation status alone often fails to capture the biological heterogeneity and context dependence of NRF2 pathway dysregulation. In recent years, growing evidence has highlighted the NRF2 activation state as a clinically relevant feature that better reflects resistance phenotypes and therapeutic liabilities than genotyping alone. The recent work by Härkönen et al, published in The Journal of Pathology, suggests that anchoring genotype to phenotype using functional readouts is essential for defining NRF2 hyperactivity. Mechanistic studies further suggest that NRF2 hyperactivity can impose context-dependent metabolic liabilities. We discuss the next steps towards clinical translation, including prospective NRF2 activation-state stratification, integration of immune context for immunotherapy, and biomarker evaluation of redox and metabolic combinations based on NRF2-associated vulnerabilities. © 2026 The Pathological Society of Great Britain and Ireland.
Insights
Non-small cell lung cancer (NSCLC) treatment is improved by understanding the Nuclear factor erythroid 2-related factor 2 (NRF2) activation state. Functional readouts, not just mutations, reveal NRF2 hyperactivity and its link to metabolic vulnerabilities.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Non-small cell lung cancer (NSCLC) poses a significant mortality burden, with limited efficacy of current systemic therapies.
- Focus on Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (NRF2) axis mutations has not fully captured pathway dysregulation.
- NRF2 pathway activation state is emerging as a critical determinant of resistance and therapeutic liabilities in NSCLC.
Purpose of the Study:
- To emphasize the importance of functional readouts for assessing NRF2 pathway activity in NSCLC.
- To explore the link between NRF2 hyperactivity and context-dependent metabolic liabilities.
- To outline future clinical translation strategies for NRF2 activation-state stratification.
Main Methods:
- Review of recent mechanistic and translational studies on the NRF2 pathway in NSCLC.
- Analysis of the relationship between NRF2 genotype and phenotype using functional readouts.
- Investigation of metabolic consequences of NRF2 hyperactivity.
Main Results:
- NRF2 activation state, assessed functionally, is a more accurate indicator of pathway dysregulation than mutation status alone.
- NRF2 hyperactivity is associated with context-dependent metabolic liabilities.
- Genotype-phenotype correlation is crucial for defining NRF2 hyperactivity.
Conclusions:
- Anchoring genotype to phenotype via functional readouts is essential for understanding NRF2 hyperactivity in NSCLC.
- NRF2 hyperactivity presents context-specific metabolic vulnerabilities that can be therapeutically exploited.
- Future clinical strategies should include NRF2 activation-state stratification, immune context integration, and redox/metabolic biomarker evaluation.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
06:26Single Cell Analysis Of Transcriptionally Active Alleles By Single Molecule FISH
Published on: September 20, 2020
